Sage Journals: Discover world-class research

Abstract

T cell costimulatory pathways are believed to play important roles in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus(SLE). Animal models of SLE support the role of T cell costimulation in B cell activation and the production of autoantibodies. CTLA4Ig is a novel fusion protein that interferes with T cell costimulation by inhibiting the CD28-B7 interaction. A pivotal study demonstrated the ability of CTLA4Ig to suppress the production of anti-dsDNA antibodies and decrease nephritisin lupus prone mice. In an additionalstudy, the combination of CTLA4Ig and cyclophosphamidesignificantly reduced proteinuria and prolonged survival in mice with advanced nephritis. In small human studies of psoriasis and rheumatoid arthritis, CTLA4Ig improved clinical outcomes and was well tolerated. These promising experienceswith CTLA4Ig have paved the way for future studies in human SLE.

Keywords

CTLA4Ig review systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Abbas A , Lichtman A , Pober J. Cellular and molecular immunology, fourth edition. Philadelphia: W.B. Saunders Company , 2000.

Waterhouse P , Penninger J , Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4 . Science 1995; 270: 985-989 .

Sayegh M , Turka L. The role of T cell costimulation activation pathways in transplant rejection . New Engl J Med 1998; 338: 1813-1821 .

Reiser H , Stadecker M. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases . New Engl J Med 1996; 335: 1369-1377 .

Linsley P , Brady W , Urnes M , Grosmaire L , Damle N , Ledbetter J. CTLA4 is a second receptor for the B cell activation antigen B7 . J Exp Med 1991; 174: 561-569 .

Linsley P , Wallace P , Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA4 T cell activation molecule . Science 1992; 257: 792-795 .

Wallace P , Rodgers J , Leytze G , Johnson J , Linsley P. Induction and reversal of long-lived specific unresponsivenessto a T-dependent antigen following CTLA4Ig treatment . J Immunol 1995; 154: 5885-5895 .

Tivol E , Boyd S , McKeon S et al. CTLA4Ig prevents lymphoproliferative and fatal multiorgan tissue destruction in CTLA-4-deficient mice . J Immunol 1997; 158: 5091-5094 .

Lenschow D , Ho S , Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse . J Exp Med 1995; 181: 1145-1155 .

10.

Chandraker A , Azuma H , Nadeau K et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection . J Clin Invest 1998; 101: 2309-2318 .

11.

Khoury S , Akalin E , Chandraker A. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system . J Immunol 1995; 155: 4521-4524 .

12.

Levisetti M , Padrid P , Szot G et al. Immunosuppressiveeffects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet cell transplantation . J Immunol 1997; 159: 5187-5191 .

13.

Kirk A , Harlan D , Armstrong N et al. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates . Proc Nat Acad Sci 1997; 94: 8789-8794 .

14.

Krieger N , Yuh D , McIntyre W et al. Prolongation of cardiac graft survival with anti-CD4Ig plus CTLA4Ig in primates . J Surg Res 1998; 76: 174-178 .

15.

Finck B , Linsley P , Wofsy D. Treatment of murine lupus with CTLA4Ig . Science 1994; 265: 1225-1227 .

16.

Mihara M , Tan I , Chuzhin Y et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus . J Clin Invest 2000; 106: 91-101 .

17.

Daikh D , Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide . J Immunol 2001; 166: 2913-2916 .

18.

Abrams J , Lebwohl M , Guzzo C et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris . J Clin Invest 1999; 103: 1243-1252 .

19.

Moreland L , Alten R , Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis - a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA4Ig and LEA29Y eighty-five days after the first infusion . Arthritis Rheum 2002; 46: 1470-1479 .

20.

Kremer J , Westhovens R , Leon M et al. A phase 2B multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CT-A4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate . Arthritis Rheum 2002; 46: S203-S203 (abstract).

21.

Weinblatt M , Schiff M , Goldman M , Kremer J , Breazna A , Becker JC. A pilot, multi-center, randomized, double-blind, placebo controlled trial of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis . Arthritis Rheum 2002; 46: S204-S204 (abstract).

CTLA4Ig: a novel inhibitor of costimulation

Abstract

Keywords

Get full access to this article

References